(MENAFN) A groundbreaking Nature study reveals that SARS-CoV-2 mRNA vaccines—initially developed to combat the pandemic—may enhance the effectiveness of certain cancer therapies.

Scientists discovered that the immune activation generated by these vaccines could prime tumors to respond better to immune checkpoint inhibitors (ICIs), medications that enable the body's defense system to target malignant cells.

While ICIs have revolutionized outcomes for melanoma and lung cancer patients, a significant portion of cases remain unresponsive. Numerous patients harbor what clinicians call "immunologically cold" tumors—growths with insufficient immune presence for these drugs to function properly.

The research team's breakthrough findings demonstrate that coronavirus mRNA vaccines can reverse this resistance.

"mRNA vaccines targeting SARS-CoV-2 also sensitize tumors to ICIs," the authors wrote.

Mouse model studies showed the vaccines generated a robust surge of type I interferon, a compound that amplifies the immune system's capacity to identify and eliminate defective cells. This process subsequently activated CD8+ T cells, critical immune warriors capable of eliminating cancerous tissue.

Scientists further observed that pairing the mRNA vaccine with ICI therapy dramatically reduced tumor progression, especially in "immunologically cold" malignancies that typically defy immunotherapy approaches.

These results carry profound implications for oncology. Previously, physicians possessed limited options for making immunotherapy viable in patients whose tumors fail to naturally recruit immune cells.

Though the investigation remains in preliminary phases and requires validation through human clinical trials, specialists note it unveils compelling therapeutic avenues.

Ultimately, a pharmaceutical tool engineered to neutralize a viral pathogen may simultaneously empower the human body to combat cancer.

MENAFN25102025000045017169ID1110246106